Mouse CD20 Antibody (clone 18B12)

Mouse IgG2a - For in vivo use

ABOUT

Recombinant murinized CD20 antibody for in vivo use

Anti-mCD20-mIgG2a InvivoFit™ is a mouse anti-mouse monoclonal antibody (mAb) featuring the variable region of the previously described anti-mCD20 18B12 clone [1]. Using recombinant technology, the original 18B12 murine IgG1 constant region has been replaced with a murine IgG2a format which mediates potent cytotoxic functions [2].

CD20 is a cell surface protein mainly expressed by resting and activated B lymphocytes, but not plasma cells [3]. CD20 is also expressed by most malignant B cells, which makes it an ideal target for antibody-based immunotherapies against lymphoid malignancies [3-6].

 

The anti-mCD20 18B12 mAb is commonly used for in vivo depletion of the CD20+ B cell population to study the role of B cells in various immune responses, including auto-immune or tumoral contexts [1, 7].
Anti-mCD20-mIgG2a is provided in an InvivoFit™ grade, a high-quality standard specifically adapted to in vivo

Key features of Anti-mCD20-mIgG2a InvivoFit™:

  • Derives from the 18B12 clone, mouse IgG1, κ
  • Features the mIgG2a isotype (constant region)
  • Filter-sterilized (0.2 µm), endotoxin level < 1 EU/mg
  • Suitable for parental delivery in mice (azide-free)
  • Low aggregation < 5%
  • Produced in animal-free facilities and defined media


Anti-mCD20-mIgG2a InvivoFit™ is produced in Chinese hamster ovary (CHO) cells and purified by affinity chromatography with protein A. The specific binding of this mAb to cell surface mCD20 and its in vivo depleting function have been confirmed (see Figures).

 

References:

1. Ahuja A. et al., 2007. Depletion of B cells in murine lupus: efficacy and resistance. J. Immunol. 179(5):3351-3361.
2. Nimmerjahn F. & Ravetch J.V., 2005. Divergent immunoglobulin g subclass activity through selective Fc receptor binding. Science. 310(5753):1510-2.
3. Uchida J. et al., 2004. Mouse CD20 expression and function  Int Immunol. 16(1):119-29.
4. Cvetković R.S. & Perry C.M., 2006. Rituximab. Drugs. 66:791-820.
5. Freeman C. L. & Sehn L. H., 2018. A tale of two antibodies: obinutuzumab versus rituximab. Br. J. Haematol. 182(1):29-45.
6. Soe Z. N. & Allsup D., 2017. The use of ofatumumab in the treatment of B-cell malignancies. Future Oncol. 13(29):2611-2628. 
7. Maglioco A. et al., 2017. B cells inhibit the antitumor immunity against an established murine fibrosarcoma. Oncology letters. 13(5):3225-3232.

All products are for research use only, and not for human or veterinary use.

InvivoFit™

InvivoFit™ is a high-quality standard specifically adapted for in vivo studies. 
InvivoFit™ products are filter-sterilized (0.2 µm) and filled under strict aseptic conditions in a clean room. The level of bacterial contaminants (endotoxins and lipoproteins) in each lot is verified using a LAL assay and a TLR2 and TLR4 reporter assay

SPECIFICATIONS

Specifications

Target

CD20

Target species

Mouse

Species
Mouse
Isotype
mIgG2a
kappa
Clone
18B12
Tag
Tag-free
Source
CHO cells
Production details
Animal-free
Purification
Protein A
Formulation buffer

Sodium chloride, sodium phosphate buffer, saccharose

Preservative
Azide-free
Purity
≥ 95 %
Aggregation

< 5%

Appearance (form)
Lyophilized
Reconstitution buffer
Sterile water (not provided)
Sterility

0.2 µm filtration

Endotoxin

Negative (tested using EndotoxDetect™ assay)

Tested applications

Flow cytometry, in vivo depletion

Quality control

Each lot is functionally tested and validated.

CONTENTS

Contents

  • Product: 
    Anti-mCD20-mIgG2a InvivoFit™
  • Cat code: 
    mcd20-mab10-1
  • Quantity: 
    1 mg

Shipping & Storage

  • Shipping method:  Room temperature
  • Storage:

    • -20 °C
    Stability: -20°C for up to 1 year

    Caution:

    • Avoid repeated freeze-thaw cycles

Details

CD20 Background:

The cluster of differentiation 20 (CD20, aka Ly-44, or B-lymphocyte antigen) is a ~35 KDa cell surface protein mainly expressed by resting and activated B lymphocytes, but not plasma cells [1]. CD20 is also expressed by most malignant B cells, which makes it an ideal target for antibody-based immunotherapies against lymphoid malignancies [1-4]. For example, Rituximab, Obinutuzumab, and Ofatumumab are FDA-approved monoclonal anti-human CD20 antibodies for the treatment of B-cell non-Hodgkin’s lymphoma and B-cell chronic lymphocytic leukemia [1-4]. These antibodies mediate the target cell destruction through different mechanisms including direct signaling of apoptosis, complement activation (CDC), and cell-mediated cytotoxicity (ADCC).

 

References:

1. Uchida J. et al., 2004. Mouse CD20 expression and function  Int Immunol. 16(1):119-29.
2. Cvetković R.S. & Perry C.M., 2006. Rituximab. Drugs. 66:791-820.
3. Freeman C. L. & Sehn L. H., 2018. A tale of two antibodies: obinutuzumab versus rituximab. Br. J. Haematol. 182(1):29-45.
4. Soe Z. N. & Allsup D., 2017. The use of ofatumumab in the treatment of B-cell malignancies. Future Oncol. 13(29):2611-2628. 

DOCUMENTS

Documents

Anti-mCD20-mIgG2a InvivoFit™

Technical Data Sheet

Validation Data Sheet

Safety Data Sheet

Certificate of analysis

Need a CoA ?

CUSTOMER SERVICE & TECHNICAL SUPPORT

Question about this product ?